Helicobacter pylori immune protection preparation and its application in preparing immune milk
By immunizing natural living bacteria and antigens of dairy cows to prepare immunized milk, the drug resistance and side effects of anti-Herrelic pylori treatment were solved, effective prevention and treatment of Helicobacter pylori infection was achieved, and a safety , easy to popularize immunological protection solutions.
Patent Information
- Application Number
- CN202311765809.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-20
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2043-12-20
AI Technical Summary
The existing anti-Herrelic pylori treatment methods have drug resistance problems and side effects, and vaccine immunity is difficult to effectively clear gastric infections and cannot eliminate infections by itself. It is necessary to have a safer and more effective immune prevention and treatment method.
The cows were immunized with natural living bacteria and natural/recombinant antigens of Helicobacter pylori to prepare immunized milk, and the high titer sIgA and IgG antibodies in the milk produced mucosal immune protection and neutralization effects on Helicobacter pylori.
It has achieved effective prevention and treatment of Helicobacter pylori infection, avoided antibiotic resistance and side effects, and is safe and easy to popularize immune milk, and is suitable for the general population.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, and in particular to a Helicobacter pylori immune protection preparation and application thereof in preparing immune milk. Background Art
[0002] Helicobacter pylori (H. pylori) is a common pathogen of digestive tract diseases including gastritis and peptic ulcer, and is also related to the occurrence of gastric cancer. Therefore, H. pylori infection seriously threatens national health, and the prevention and treatment of related diseases also consumes a large amount of social medical and health resources. At present, for Helicobacter pylori infection, especially virulent Helicobacter pylori infection, multi-therapy including antibiotics is usually used for sterilization treatment to achieve the purpose of clearing infection and treating related diseases. However, with the widespread development of anti-Helicobacter pylori therapy based on antibiotics, Helicobacter pylori resistance to antibiotics has become a problem that cannot be ignored in clinical practice. The direct consequence of resistance is that the clearance rate of Helicobacter pylori by standard therapy is greatly reduced. Moreover, antibiotics used for anti-Helicobacter pylori treatment will destroy the normal flora in the body and the normal microecological system that maintains the health of the body during use, posing a major threat and harm to the health of infected people. At the same time, the anti-Helicobacter pylori treatment also includes proton pump inhibitors and bismuth agents. The side effects of proton pump inhibitors include gastrointestinal adverse reactions, liver damage, allergic reactions, kidney damage, neuropsychiatric system damage, visual impairment, endocrine and reproductive system adverse reactions and circulatory system adverse reactions, etc. The side effects of bismuth agents include the nervous system: bismuth poisoning and bismuth encephalopathy; digestive system: ammonia taste in the mouth, diarrhea, bismuth in the stool, gray-black stool; urinary system: renal function damage and renal failure; musculoskeletal system: osteoarthritis; drug interaction risks, etc. Current data show that the success rate of anti-Helicobacter pylori treatment has dropped from more than 95% at the beginning to 60-80%. Repeated antibacterial treatment after treatment failure not only leads to the deterioration of Helicobacter pylori resistance, but also repeated use of antibiotics will lead to the destruction of the normal flora and microecology of the infected body, seriously threatening the health of patients; at the same time, repeated treatment will inevitably consume medical expenses and increase medical burden, occupying precious medical resources. Therefore, the current conventional anti-Helicobacter pylori treatment causes great harm to the body while clearing Helicobacter pylori infection. Doctors should carefully weigh the benefits and costs of the above treatment and treat the infected people under the premise that the harm to the patient can be controlled.
[0003] There are two strategies to deal with the current difficulties in the treatment of Helicobacter pylori infection. One is to conduct in vitro drug sensitivity tests on Helicobacter pylori while maintaining the existing treatment plan, select sensitive antibiotics based on the results of in vitro antibiotic sensitivity tests, and avoid the use of resistant antibiotics, thereby guiding the design and formulation of clinical treatment plans, and treating Helicobacter pylori more accurately, greatly improving the success rate of treatment and avoiding treatment failure. The other strategy is to choose non-antibiotic Helicobacter pylori elimination methods, especially using related products prepared based on immunological methods and principles to eliminate Helicobacter pylori infection.
[0004] There are two options for immune prevention and treatment of pathogenic microorganism infections, namely active immunity and passive immunity. Active immunity is to prepare a non-pathogenic inactivated body or key functional protein of the pathogen as a vaccine, and through vaccination, induce the body to produce antibodies and immune effector molecules against specific pathogenic microorganisms, so that the body can be immune to specific pathogenic microorganisms; passive immunity refers to the direct use of immune effector molecules including antibodies to help the body produce and enhance immunity to specific pathogens, thereby quickly eliminating pathogen infection. Similarly, the above two methods and routes can also be applied to the prevention and treatment of Helicobacter pylori infection. The immunological elimination method for Helicobacter pylori infection and the treatment of related diseases also include active immunity and passive immunity. One is a Helicobacter pylori vaccine based on active immunity, which uses Helicobacter pylori-related bacterial components to immunize the body, induce the body to produce corresponding protective antibodies, and thus protect the body from Helicobacter pylori infection. However, since Helicobacter pylori infection is a local infection that colonizes the gastric mucosa, even if vaccination can induce the appearance of corresponding protective antibodies and high-titer protective antibodies appear in the circulatory system, these antibodies are difficult to enrich in the gastric cavity where Helicobacter pylori is colonized to produce a protective effect. The fact that can be supported is that for most Helicobacter pylori infected people, there are high-titer Helicobacter pylori antibodies in their serum, but these antibodies do not play an observable protective role against the infected people, let alone show the effect of clearing existing infections. A large number of studies have shown that once Helicobacter pylori infects the human body, if the infected person does not receive systematic and standardized anti-Hp treatment, the Hp infection cannot be eliminated by itself.
[0005] Based on the above status of anti-Helicobacter pylori treatment, we urgently need to develop new therapeutic drugs and methods to deal with Hp infection. They should not only be safer and more effective, but also play an immune preventive role for the general susceptible population. At the same time, they should have the greatest applicability and can be quickly and easily applied to all general populations. Summary of the invention
[0006] In view of this, the technical problem to be solved by the present invention is to provide a Helicobacter pylori immune protection preparation and its use in the preparation of immune milk. The present invention provides an effective, safe and easy-to-popularize Helicobacter pylori immune protection preparation, as well as its use in the preparation of immune milk. The prepared immune milk is safe and has a high Helicobacter pylori antibody titer.
[0007] The present invention provides an immunoprotective preparation for Helicobacter pylori, comprising at least one of Helicobacter pylori, a natural antigen and a recombinant antigen of Helicobacter pylori, wherein:
[0008] The natural antigens include whole bacterial proteins of Helicobacter pylori;
[0009] The recombinant antigen includes at least one of cytotoxin-associated protein A, vacuolating toxin, urease and heat shock protein, and the urease includes urease A and / or urease B.
[0010] Compared with the prior art, the present invention uses natural live Helicobacter pylori for immunization of dairy cows, and uses natural antigens and recombinant antigens of Helicobacter pylori for comprehensive immunization of dairy cows. The synergistic immunity of the three immunogens further improves the immune effect of the immune protection preparation, thereby obtaining a more excellent technical effect.
[0011] The invention provides application of the immune protection preparation in preparing immune milk.
[0012] The invention provides a method for preparing immune milk, comprising the step of using the immune protection preparation to immunize a dairy cow to obtain the immune milk.
[0013] In some embodiments, the immunization comprises:
[0014] Feeding the live bacteria of Helicobacter pylori to dairy cows; and / or
[0015] The natural antigen and / or recombinant antigen of Helicobacter pylori is taken to perform injection immunization on dairy cows.
[0016] In some specific embodiments, the feeding comprises using 5×10 10 The live bacteria of CFU Helicobacter pylori are fed to dairy cows three times a day for 7 consecutive days.
[0017] In other specific embodiments, the method for preparing the natural antigen comprises: taking the Helicobacter pylori, lysing it with lysozyme, and then ultrasonically disrupting it, collecting the lysate supernatant and the precipitate, dissolving the precipitate with urea, and centrifuging it, dialyzing the supernatant after the centrifugation to obtain the precipitation supernatant, and mixing the lysate supernatant and the precipitation supernatant to obtain the natural antigen of the Helicobacter pylori;
[0018] The preparation method of the recombinant antigen comprises: constructing recombinant plasmids of cytotoxin-associated protein A, vacuolating toxin, urease and heat shock protein respectively, and obtaining the recombinant antigen after prokaryotic expression and purification.
[0019] In some embodiments, the urease A has:
[0020] (1) the amino acid sequence shown in SEQ ID NO: 11; or
[0021] (2) A sequence in which one or more amino acids are substituted, deleted, added and / or replaced based on the amino acid sequence shown in (1); or
[0022] (3) an amino acid sequence that is at least 80% identical to the amino acid sequence shown in (1) or (2);
[0023] The urease B has:
[0024] (4) the amino acid sequence shown in SEQ ID NO: 12; or
[0025] (5) A sequence in which one or more amino acids are substituted, deleted, added and / or replaced based on the amino acid sequence shown in (4); or
[0026] (6) an amino acid sequence that is at least 80% identical to the amino acid sequence shown in (4) or (5);
[0027] The vacuolating toxin has:
[0028] (7) the amino acid sequence shown in SEQ ID NO: 13; or
[0029] (8) A sequence in which one or more amino acids are substituted, deleted, added and / or replaced based on the amino acid sequence shown in (7); or
[0030] (9) an amino acid sequence that is at least 80% identical to the amino acid sequence shown in (7) or (8);
[0031] The cytotoxin-associated protein A has:
[0032] (10), the amino acid sequence shown in SEQ ID NO: 14; or
[0033] (11) A sequence in which one or more amino acids are substituted, deleted, added and / or replaced based on the amino acid sequence shown in (10); or
[0034] (12) an amino acid sequence that is at least 80% identical to the amino acid sequence of (10) or (11);
[0035] The heat shock protein has:
[0036] (13), the amino acid sequence shown in SEQ ID NO: 15; or
[0037] (14) A sequence in which one or more amino acids are substituted, deleted, added and / or replaced based on the amino acid sequence shown in (13); or
[0038] (15) An amino acid sequence that is at least 80% identical to the amino acid sequence shown in (13) or (14).
[0039] Furthermore, the reagent for injection immunization also includes complete Freund's adjuvant, and the reagent is obtained by mixing the complete Freund's adjuvant with the natural antigen, the recombinant antigen, or a mixture of the natural antigen and the recombinant antigen. The injection immunization includes taking the reagent and injecting it subcutaneously at the proximal end of the cow's limbs and both sides of the buttocks.
[0040] In some embodiments, the dairy cows are 16-month-old black and white spotted cows, and the dairy cows are pre-immunized with drugs that inhibit gastric motility (such as scopolamine, etc.) and drugs that inhibit gastric acid secretion (such as omeprazole, etc.).
[0041] After a lot of preliminary research and experiments, it was proved that 16-month-old black and white cattle have good immune reactivity to natural and recombinant antigen proteins of Helicobacter pylori. After immunization, high titers of anti-Helicobacter pylori sIgA antibodies and IgG antibodies can be produced in the cow's milk. The use of cholinergic nerve inhibitors and proton pump inhibitors can weaken the gastric motility of immunized animals and inhibit the secretion of gastric acid, which is conducive to the presence of oral live bacteria in the gastric cavity, improves the immune efficiency, and then stimulates the immune cows to produce high titers of Helicobacter pylori-specific antibodies, thereby obtaining a better immune effect.
[0042] The invention provides immune milk prepared by the preparation method.
[0043] The present invention provides an immunoprotective preparation for Helicobacter pylori comprising Helicobacter pylori, natural antigens of Helicobacter pylori and recombinant antigens. Compared with the prior art, the present invention has the following beneficial effects:
[0044] 1. The final product of the present invention is in the form of dairy products, which are common foods for people. They are more in line with common eating habits in terms of taste, nutrition, and way of taking, and are more easily accepted by people.
[0045] 2. Helicobacter pylori and related proteins only serve as immunogens to stimulate dairy cows to produce corresponding antibodies. They will not enter the blood directly, let alone the milk. Therefore, immune milk has no toxic side effects and no potential harm to health. Antibodies have no toxic side effects and will not produce drug resistance. They can be used for a long time. At the same time, milk, as a carrier, has a large output and is more economical and practical.
[0046] 3. The main functional factors are sIgA and IgG antibodies against Helicobacter pylori, which can play a very strong role in mucosal immune protection and bacterial neutralization. Therefore, it can not only be used for the prevention of Helicobacter pylori infection, but also for treatment. It has a clearing effect on Helicobacter pylori that has colonized the gastric mucosa.
[0047] 4. Nine weeks after immunization, the antibody titer in the cow serum is as high as 1:25000, and the antibody titer in the immune milk reaches 1:8000. After enhanced immunization, immune milk can be obtained stably and continuously. BRIEF DESCRIPTION OF THE DRAWINGS
[0048] Figure 1 The SDS-PAGE electrophoresis diagram and Western-Blot detection result diagram of CagA protein are shown, wherein, in the SDS-PAGE electrophoresis diagram, M: protein markers, lane 1: CagA protein, and in the Western-Blot detection result diagram, lane 1: CagA protein;
[0049] Figure 2 The SDS-PAGE electrophoresis diagram and Western-Blot detection result diagram of VacA protein are shown, wherein, in the SDS-PAGE electrophoresis diagram, M: protein markers, lane 1: VacA protein, and in the Western-Blot detection result diagram, lane 1: VacA protein;
[0050] Figure 3 The SDS-PAGE electrophoresis diagram and Western-Blot detection result diagram of UreA protein are shown, wherein, in the SDS-PAGE electrophoresis diagram, M: protein markers, lane 1: UreA protein, and in the Western-Blot detection result diagram, lane 1: UreA protein;
[0051] Figure 4 The SDS-PAGE electrophoresis diagram and Western-Blot detection result diagram of UreB protein are shown, wherein, in the SDS-PAGE electrophoresis diagram, M: protein markers, lane 1: UreB protein, and in the Western-Blot detection result diagram, lane 1: UreB protein;
[0052] Figure 5The SDS-PAGE electrophoresis diagram and Western-Blot detection result diagram of groEL protein are shown, wherein, in the SDS-PAGE electrophoresis diagram, M: protein markers, lane 1: groEL protein, and in the Western-Blot detection result diagram, lane 1: groEL protein. DETAILED DESCRIPTION
[0053] The present invention provides a Helicobacter pylori immune protection preparation and its application in the preparation of immune milk. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The method and application of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the method and application of this article without departing from the content, spirit and scope of the present invention to realize and apply the technology of the present invention.
[0054] The purpose of the present invention is to prevent and treat Helicobacter pylori infection by immunological methods (passive immunity). The implementation of the present invention is divided into two technical implementation routes. One is to strengthen the immunity of a specific breed of dairy cows by using Helicobacter pylori related immunogens to induce dairy cows to produce specific antibodies to Helicobacter pylori, thereby producing high titers of anti-Helicobacter pylori sIgA antibodies and IgG antibodies in the secreted milk. sIgA can play a mucosal immune function, and IgG antibodies can play a neutralizing and protective role. The above-mentioned immune milk can be combined with uncolonized and colonized Helicobacter pylori after oral intake. On the one hand, it can block the functional groups related to adhesion and colonization on the outer membrane of Helicobacter pylori, thereby inhibiting the successful colonization of bacteria on the gastric mucosa. On the other hand, the anti-Hp antibodies in the immune milk bind to Hp and can activate the complement system and other immune active cells to eliminate Helicobacter pylori. Another technical route for preparing immune milk is to prepare monoclonal antibodies against different virulence proteins and other functional proteins of Helicobacter pylori through genetic engineering, and add these specific antibodies to milk to prepare functional immune milk.
[0055] Immune milk rich in sIgA and IgG antibodies is prepared by active immunization of specific breeds of dairy cows: Helicobacter pylori whole-cell lysis antigen is prepared, and important virulence factors of Helicobacter pylori are artificially synthesized, including urease, vacuolating toxin (VacA), cytotoxin-associated protein A (CagA), heat shock protein (groEL) and other Helicobacter pylori-related proteins, and active immunization is performed on specific breeds of dairy cows in combination with corresponding immune adjuvants. After 4-6 weeks of immunization, the corresponding antibodies against Helicobacter pylori in dairy cow serum and milk are detected, especially secretory IgA antibodies in milk, and the titer and function of the above antibodies are evaluated to finally obtain immune milk.
[0056] The test materials used in the present invention are all common commercial products and can be purchased in the market. The present invention is further described below in conjunction with the embodiments. Example 1
[0057] 1. Preparation of Helicobacter pylori immune antigens
[0058] 1.1 Preparation of natural lysed antigens of Helicobacter pylori
[0059] 1.1.1 Collection of Helicobacter pylori strains
[0060] Clinically derived Helicobacter pylori strains were collected from patients with chronic gastritis, peptic ulcer, and gastric cancer. Electronic gastroscopy was performed on the patients, and biopsy samples were taken from patients with clear gastric tissue pathological changes for isolation and culture of Helicobacter pylori. The samples were cultured at 37°C for 3-5 days under microaerobic conditions (5% O2, 10% CO2, 85% N2) using Helicobacter pylori isolation and selection medium to obtain pure culture of Helicobacter pylori. A total of 100 strains of Helicobacter pylori were collected and frozen for later use.
[0061] The above-mentioned strains were tested for virulence factors such as CagA, VacA and urease UreA / UreB. The specific method was to sample the above-mentioned bacteria and perform SDS-PAGE electrophoresis, and then perform Western-Blot detection using anti-CagA, VacA and urease UreA / UreB corresponding antisera to confirm that the relevant Helicobacter pylori strains produce the above-mentioned virulence factors. The confirmed Helicobacter pylori strains were frozen for future use.
[0062] 1.1.2 Preparation of natural antigens of Helicobacter pylori strains
[0063] The strain was revived by selecting and isolating the culture medium using Helicobacter pylori. After 3 days of culture in a microaerobic environment, 3 mL of sterile saline was used to collect the bacteria on the surface of the culture medium for each culture medium plate, and 1 mL of lysis solution containing lysozyme was added. The bacteria were lysed using a cell ultrasonic disruptor under ice bath conditions (power setting 300-350 W, 10 seconds for 10 seconds, and 10 seconds for 10 seconds). After the end of the ultrasound, the bacterial suspension was shaken and mixed, centrifuged at 4°C 12000g for 10 min, and the supernatant and precipitate were collected separately for later use.
[0064] The above-mentioned source precipitate was further dissolved with 3 mL of 3 M urea, stirred thoroughly overnight (>12 hours) at 4°C, centrifuged at 12000 g for 30 min at 4°C, and the supernatant was taken for gradient dialysis to reduce the urea concentration in the supernatant to 0.5 M, and then the solution was placed at -80°C for use. The above two parts of the supernatant (lysis supernatant + urea-dissolved precipitation supernatant) were mixed, and the protein concentration in the supernatant was adjusted to 10-20 mg / mL, and placed at -80°C for use.
[0065] 1.2 Preparation of specific virulence-related proteins of Helicobacter pylori
[0066] 1.2.1 Cloning of Helicobacter pylori virulence-related protein genes
[0067] 1.2.1.1 Gene cloning of Helicobacter pylori urease
[0068] Helicobacter pylori urease is usually composed of large and small subunits. We amplified the urease A / B coding genes by primers targeting the urease A and urease B subunits, respectively, and used Escherichia coli such as pTrcHis2A\B\C as the expression host bacteria for prokaryotic expression of urease A and urease B. After obtaining the highly expressed products, urease A and urease B were purified to obtain the purified products of the above recombinant proteins. According to the prokaryotic expression procedure of UreA / UreB, the cagA, vacA and groEL genes were prokaryotically expressed and proteins were prepared.
[0069] The primers for amplifying the UreA, UreB, cagA, vacA and groEL genes are shown in Table 1.
[0070]
[0071] The amino acid sequence of UreA is as follows:
[0072] MDPSSRKLTPKELDKLMLHYAGELARKRKEKGIKLNYVEAVALISAHIMEEARAGKKSAAELMQEGRTLLKPDDVMDGVASMIHEVGIEAMFPDGTKLVTVHTPIEANGKLVPGELFLKNEDITINEGKKAVSVKVK NVGDRPVQIGSHFHFFEVNRYLDFDREKTFGKRLDIASGTAVRFEPGEEKSVELIDIGGNRRIFGFNALVDRQADNESKKIALHRAKERGFHGAKSDDNYVKTIKEEFEAYVEQKLISEEDLNSAVDHHHHHHH (SEQ ID NO:11)
[0073] The amino acid sequence of UreB is as follows:
[0074] MDPSSRISRKEYVSMYGPTTGDKVRLGDTDLIAEVEHDYTIYGEELKFGGGKTLREGMSQSNNPSKEELDLIITNALIVDYTGIYKADIGIKDGKIAGIGKGGNKDMQDGVKNNLSVGPATEALAGEGLIVTAGGIDTHIHFISPQQIPTAFASGVTTMIGGGTGPADGTNATTITPGRRNLKWMLRAAEEYSMNLGFLAKGNTSNDASLADQIEAGAIGFKIHEDWGTTPSAINHALDVADKYDVQVAIHTDTLNEAGCVEDTMAAIAGRTMHTFHTEGAGGGHAPDIIKVAGEHNILPASTNPTIPFTVNTEAEHMDMLMVCHHLDKSIKEDVQFADSRIRPQTIAAEDTLHDMGIFSITSSDSQAMGRVGEVITRTWQTADKNKKEFGRLKEEKGDNDNFRIKRYLSKYTINPAIAHGISEYVGSVEVGKVADLVLWSPAFFGVKPNMIIKGGFIALSQMGDANASIPTPQPVYYREMFAHHGKAKYDANITFVSQAAYDKGIKEELGLERQVLPVKNCRNITKKDMQFNDTTAHIEVNPETYHVFVDGKEVTSKPATKVSLAQLFSIFEFEAYVEQKLISEEDLNSAVDHHHHHH (SEQ ID NO: 12)
[0075] The amino acid sequence of VacA is as follows:
[0076] MEIQQTHRKINRPLVSLALVGALVSITPQQSHAAFFTTVIIPAIVGGIATGAAVGTVSGLLSWGLKQAEEANKTPDKPDKVWRIQAGRGFNNFPHKEYDLYKSLLSSKIDGGWDWGNAARHYWVKGGQWNKLEVDMKDAVGTYKLSGLINFTGGDLDVNMQKATLRLGQFNGNSFTSYKDSADRTTRVDFNAKNILIDNFLEINNRVGSGAGRKASSTVLTLQASEGITSSKNAEISLYDGATLNLASSSVKLMGNVWMGRLQYVGAYLAPSYSTINTSKVTGEVNFNHLTVGDHNAAQAGIIASNKTHIGTLDLWQSAGLNIIAPPEGGYKDKPKDKPSNTTQNNANNNQQNSAQNNNNTQVINPPNSAQKTEIQPTQVINGPFAGGKDTVVNINRINTNADGTIRVGGYKASLTTNAAHLHIGKGGINLSNQASGRSLLVENLTGNITVDGPLRVNNQVGGYALAGSNANFEFKAGTDTKNGTATFNNDISLGRFVNLKVDAHTANFKGIDTGNGGFNTLDFSGVTDKVNINKLITASTNVAIKNFNINELLVKTNGVSVGEYTHFSEDIGSQSRINTVRLETGTRSIFSGGVKFKSGEKLVIDEFYYSPWNYFDARNIKNVEITRKFASSTPENPWGTSKLMFNNLTLGQNAVMDYSQFSNLTIQGDFINNQGTINYLVRGGKVATLNVGNAAAMMFNNDIDSATGFYKPLIKINSAQDLIKNTEHVLLKAKIIGYGNVSTGTN (SEQ ID NO: 13)
[0077] The amino acid sequence of CagA is as follows:
[0078]
[0079] The amino acid sequence of groEL is as follows:
[0080] (SEQ ID NO: 15)
[0081] 1.2.2 Prokaryotic expression of Helicobacter pylori virulence proteins
[0082] The clinical strain of Helicobacter pylori was used for lysis and extraction of genomic nucleic acid, and then the gene fragment was synthesized by PCR method with the above-mentioned gene primers. The above-mentioned gene fragment was introduced into pTrcHis2c by double digestion with restriction endonucleases to construct a recombinant plasmid, which was introduced into Escherichia coli for expression, purification and identification.
[0083] The specific operation process is as follows:
[0084] 1.2.2.1 Expression and purification of Helicobacter pylori urease gene in prokaryotic cells
[0085] ① Collect fresh culture of Helicobacter pylori from clinical sources and extract genomic nucleic acid using a bacterial genomic DNA extraction kit;
[0086] ②Using bacterial genomic nucleic acid as a template, amplifying urease genes ureA and ureB, adding restriction enzyme sites on both sides of the gene, and obtaining the above gene and plasmid fragments by purifying the PCR product and plasmid pTrcHis2c and performing double enzyme digestion;
[0087] ③ Use ligase to construct the recombinant plasmid of ureA and ureB and plasmid pTrcHis2C, and identify them;
[0088] ④ Introduce the above recombinant plasmid into BL21 or Rosset to express urease;
[0089] ⑤ Pick the above E. coli carrying the expression plasmid and culture it in SOB medium. When the concentration of cultured bacteria reaches 0.4-0.6 at OD600, add IPTG with a final concentration of 1 mM to induce expression;
[0090] ⑥ Induce expression on a 37°C constant temperature shaker for 3 hours, and harvest the bacteria by low temperature centrifugation;
[0091] ⑦ After the expression of UreA and UreB proteins, protein identification and confirmation were performed using Western-BLOT;
[0092] ⑧After confirming the expression of the above protein, affinity chromatography purification was performed using a nickel particle column, eluted using imidazole elution buffer of different concentrations, the target protein was collected, and then the protein was verified and confirmed.
[0093] 1.2.2.2 Expression of Helicobacter pylori cagA / vacA / groEL genes and preparation of recombinant proteins According to the above methods and procedures, sufficient amounts of corresponding CagA, VacA and groEL proteins for dairy cow immunization were finally obtained.
[0094] The SDS-PAGE electrophoresis and Western-Blot detection results of CagA, VacA, groEL and urease UreA / UreB in the above experiment are shown in Figure 1~Figure 5 shown.
[0095] Example 2
[0096] In order to evaluate the immunogenicity of the above-mentioned Helicobacter pylori natural antigens and recombinant antigens, we designed animal experiments to evaluate the immune efficacy of the above-mentioned Helicobacter pylori-related antigens.
[0097] Evaluation method: 6-8 weeks old BALB-C female mice were immunized with natural antigens and recombinant antigens. The immunization antigens included Helicobacter pylori lysis supernatant, Helicobacter pylori precipitation urea dissolution supernatant, recombinant proteins CagA, VacA, UreaA / UreaB and GeoEL recombinant protein. The above components were mixed with complete Freund's adjuvant to prepare the immunogen, and 200uL was injected intramuscularly with an injection dose of 100ug. Immunization was performed, followed by booster immunization every week for 2 consecutive weeks. Mouse serum was collected in the 4th week, and the Helicobacter pylori-specific serum antibody titer in the serum was detected by ELISA. The results are shown in Tables 2 and 3.
[0098]
[0099] Table 2 shows the serum antibody titers produced by animals immunized with different immunogens alone or in combination. The results show that higher antibody titers can be obtained by immunizing animals with two antigen components in combination.
[0100]
[0101] Table 3 shows that higher antibody titers can be obtained by co-immunizing animals with natural antigens (bacterial lysis supernatant + precipitated urea supernatant) and recombinant antigens (UreA / UreB, CagA, VacA and GroEL).
[0102] The results showed that the highest antibody titer level could be obtained by immunizing animals with both natural Helicobacter pylori antigens and recombinant antigens. Therefore, we used the above natural antigens and recombinant antigens to immunize cows in subsequent immunization to obtain the highest titer of corresponding antibodies.
[0103] Example 3
[0104] Immunization of dairy cows
[0105] 1. Selection of dairy cow strains
[0106] Select 16-month-old black and white cattle, and test to make sure they are free of foot-and-mouth disease, anthrax, tuberculosis, etc. and weigh 300-350 kg.
[0107] 2 Pre-immunization treatment
[0108] Gastric motility inhibitors and antacids
[0109] Before antigen immunization, scopolamine and omeprazole were used to intervene the immunized dairy cows, scopolamine 1g / time, twice a day; omeprazole 1g / time, twice a day. The above drugs were used for a total of 1 week.
[0110] 3. Choice of immunization regimen:
[0111] 3.1 Immunization with oral live bacteria
[0112] Oral feeding of Helicobacter pylori whole bacterial liquid in experimental dairy cows
[0113] Helicobacter pylori was revived on the culture medium, then subcultured and cultured at 37°C for 3 days. 50 mL × 10 9 CFU / mL, the above culture solution containing fresh live bacteria was added to the feed of immunized dairy cows that had been fasting for 1 day, three times a day, for 7 consecutive days; blood samples and milk samples were collected 2 weeks, 3 weeks, 6 weeks and 9 weeks after the end of immunization to detect Helicobacter pylori-specific antibodies, and the results are shown in Tables 4 and 5.
[0114] 3.2 Immunization with natural antigens of Helicobacter pylori
[0115] Take the Helicobacter pylori lysis supernatant (natural immunogen, including natural bacterial lysis supernatant and precipitated urea supernatant) and add an equal amount of Freund's complete adjuvant to fully emulsify the Helicobacter pylori antigen lysis supernatant. The specific methods include:
[0116] i. Suspension method: Take 15 mL of complete Freund's adjuvant and add 15 mL of Helicobacter pylori supernatant. Add the adjuvant first, then slowly add the Helicobacter pylori supernatant while suspending the adjuvant in a suspension vessel to fully mix the antigen and adjuvant until a viscous emulsion is formed;
[0117] ii. Mixing by syringe: Add 15 mL of complete Freund's adjuvant to 15 mL of Helicobacter pylori supernatant and aspirate them into two 150 mL syringes respectively. Connect the two syringes with a thin rubber tube, exhaust all the air, push the antigen into the adjuvant first, and then push the syringes alternately until a viscous emulsion is formed and it is difficult to push.
[0118] Each dairy cow was immunized with 30 mL of the emulsified antigen. 5 mL of the emulsified antigen was subcutaneously injected into the proximal end of each limb, and then 5 mL of the emulsified antigen was injected into each side of the cow's buttocks.
[0119] After three and six weeks, booster immunization was performed according to the above method. 10 mL of blood samples and 500 mL of milk samples were collected from the immune cows every week to detect the corresponding anti-Helicobacter pylori antibodies and titers. IgG antibodies were detected in blood samples 2, 3, 6 and 9 weeks after immunization, and sIgA antibodies and IgG antibodies were detected in milk. The results are shown in Tables 4 and 5.
[0120] 3.3 Immunization with recombinant Helicobacter pylori antigens (UreA / UreB, CagA, VacA and GeoEL)
[0121] Take the Helicobacter pylori recombinant antigen and add an equal amount of Freund's complete adjuvant to fully emulsify the Helicobacter pylori antigen lysis supernatant. The specific method includes:
[0122] i. Suspension method: Take 15 mL of complete Freund's adjuvant and add 15 mL of Helicobacter pylori supernatant. Add the adjuvant first, then slowly add the Helicobacter pylori supernatant while suspending the adjuvant in a suspension vessel to fully mix the antigen and adjuvant until a viscous emulsion is formed;
[0123] ii. Mixing by syringe: Add 15 mL of complete Freund's adjuvant to 15 mL of Helicobacter pylori supernatant and aspirate them into two 150 mL syringes respectively. Connect the two syringes with a thin rubber tube, exhaust all the air, push the antigen into the adjuvant first, and then push the syringes alternately until a viscous emulsion is formed and it is difficult to push.
[0124] Each dairy cow was immunized with 30 mL of the emulsified antigen. 5 mL of the emulsified antigen was subcutaneously injected into the proximal end of each limb, and then 5 mL of the emulsified antigen was injected into each side of the cow's buttocks.
[0125] After three and six weeks, booster immunization was performed according to the above method. 10 mL of blood samples and 500 mL of milk samples were collected from the immune cows every week to detect the corresponding anti-Helicobacter pylori antibodies and titers. IgG antibodies were detected in blood samples 2, 3, 6 and 9 weeks after immunization, and sIgA antibodies and IgG antibodies were detected in milk. The results are shown in Tables 4 and 5.
[0126] 3.4 Oral vaccination of dairy cows with whole-bacteria immunization + Helicobacter pylori natural antigens (natural bacterial lysis supernatant and precipitated urea supernatant)
[0127] According to the above scheme, while dairy cows are being immunized with live bacteria orally, they are also immunized with Helicobacter pylori natural antigens. After the booster immunization with natural antigens is completed, serum and milk samples are collected to detect the antibody titers and levels of different antibodies in the samples.
[0128] 3.5 Oral vaccination of dairy cows with whole bacteria + immunization with recombinant Helicobacter pylori antigens (UreA / UreB, CagA, VacA and GeoEL)
[0129] According to the above scheme, while the dairy cows were immunized with live bacteria orally, they were also immunized with Helicobacter pylori recombinant antigens. After the completion of the booster immunization with the recombinant antigen, serum and milk samples of the dairy cows were collected 2 weeks, 3 weeks, 6 weeks and 9 weeks after the end of the immunization, and the antibody titers and levels of different antibodies in the samples were tested. The results are shown in Tables 4 and 5.
[0130] 3.6 Oral vaccination of dairy cows with whole-bacteria vaccine + combined vaccination with natural and recombinant Helicobacter pylori antigens
[0131] While feeding the above live bacteria, the immune cows were immunized with Helicobacter pylori natural antigens and recombinant antigens at the same time. The above-prepared Helicobacter pylori natural antigens (natural antigen supernatant + urea supernatant) and Helicobacter pylori recombinant antigens (UreA / UreB, CagA, VacA and GroEL) were mixed in equal amounts to prepare the immunogen, and then mixed with complete Freund's adjuvant according to the previous method to prepare the immune suspension. The specific method is as follows:
[0132] The above mixed immunogen and Freund's complete adjuvant are mixed in equal amounts to prepare an immune emulsion suspension, and the Helicobacter pylori antigen is fully emulsified. The specific method includes:
[0133] i. Suspension method: Take 15 mL of complete Freund's adjuvant and add 15 mL of Helicobacter pylori supernatant. Add the adjuvant first, then slowly add the Helicobacter pylori supernatant while suspending the adjuvant in a suspension vessel to fully mix the antigen and adjuvant until a viscous emulsion is formed;
[0134] ii. Mixing by syringe: Add 15 mL of complete Freund's adjuvant to 15 mL of Helicobacter pylori supernatant and aspirate them into two 150 mL syringes respectively. Connect the two syringes with a thin rubber tube, exhaust all the air, push the antigen into the adjuvant first, and then push the syringes alternately until a viscous emulsion is formed and it is difficult to push.
[0135] After the 1:1 mixture of antigen and adjuvant is prepared, it is refrigerated at 2-8℃ for subsequent immunization injections:
[0136] Blood and milk samples were collected from cows 2, 3, 6 and 9 weeks after the end of immunization to detect the corresponding specific antibodies. The results of the cow serum antibody level (IgG) are shown in Table 4, and the results of the cow milk antibody level (IgG+sIgA) are shown in Table 5.
[0137]
[0138]
[0139] The above results show that after single and combined immunization with different antigens, different titers of specific antibodies were produced in serum and milk samples, among which oral feeding + natural and recombinant antigen immunization of dairy cows can obtain the highest Helicobacter pylori antibody titer. Therefore, the Helicobacter pylori immunization milk program we finally determined adopts a combined immunization program of oral feeding + natural and recombinant antigen immunization.
[0140] 4. Enhanced immunity and collection of immune milk
[0141] After the dairy cows complete the above-mentioned combined immunization (9th week), immune milk can be collected and sequential booster immunizations are performed once with Helicobacter pylori natural antigen and recombinant antigen respectively at intervals of three months to ensure the production of high titer sIgA antibodies and IgG antibodies in the milk.
[0142] Sequential booster immunization method for dairy cows:
[0143] The preparation of natural antigens and artificial recombinant antigens of Helicobacter pylori is as before, and booster immunization is performed 3 months after the immune milk is collected. First, 50 mL of natural antigen + adjuvant is used for booster immunization according to the above method; 3 months later, 50 mL of recombinant antigen + adjuvant of Helicobacter pylori is used for booster immunization, and so on for sequential booster immunization, so as to ensure that the cows secrete high titers of sIgA antibodies and IgG antibodies in the milk.
[0144] The above are only preferred embodiments of the present invention. It should be pointed out that, for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A method for preparing immune milk, characterized in that: Live bacteria of Helicobacter pylori are fed to 16-month-old black and white dairy cows, and natural antigens and recombinant antigens of Helicobacter pylori are injected to immunize 16-month-old black and white dairy cows; before antigen immunization, scopolamine and omeprazole are used to intervene the immunized dairy cows for 1 week, scopolamine 1g / time, twice a day; omeprazole 1g / time, twice a day; The live bacteria feeding dairy cows comprises: Helicobacter pylori was revived on the culture medium, then subcultured and cultured at 37°C for 3 days. 50 mL × 10 9 CFU / mL, the above-mentioned culture solution containing fresh live bacteria was added into the feed of immune dairy cows that had been fasted for 1 day after intervention with scopolamine and omeprazole, three times a day, for 7 consecutive days; The injection immunization of the natural antigen of Helicobacter pylori comprises: The Helicobacter pylori is taken, lysed by lysozyme, ultrasonically disrupted, and then the lysis supernatant and precipitate are collected. The precipitate is dissolved by urea and centrifuged. The supernatant after the centrifugation is dialyzed to obtain the precipitation supernatant. The lysis supernatant and the precipitation supernatant are mixed to obtain the natural antigen of the Helicobacter pylori. Then, an equal amount of Freund's complete adjuvant is added to fully emulsify the Helicobacter pylori antigen lysis supernatant. 30 mL of the emulsified antigen is taken from each dairy cow for immunization. 5 mL of the emulsified antigen is subcutaneously injected into the proximal ends of the four limbs respectively, and then 5 mL of the emulsified antigen is injected into each side of the dairy cow's buttocks. After three weeks and six weeks, booster immunization is performed once according to the above method; The injection immunization of the recombinant antigen comprises: Recombinant Helicobacter pylori antigens urease A, urease B, vacuolating toxin, cytotoxin and heat shock protein are mixed and then emulsified with an equal amount of Freund's complete adjuvant. 30 mL of the emulsified antigen is taken from each dairy cow for immunization. 5 mL of the emulsified antigen is injected subcutaneously into the proximal ends of the four limbs, and then 5 mL of the emulsified antigen is injected into each side of the cow's buttocks. After three and six weeks, booster immunization is performed once according to the above method. Among the recombinant antigens, the amino acid sequence of urease A is shown in SEQ ID NO: 11; the amino acid sequence of urease B is shown in SEQ ID NO: 12; the amino acid sequence of vacuolating toxin is shown in SEQ ID NO: 13; the amino acid sequence of cytotoxin is shown in SEQ ID NO: 14; and the amino acid sequence of heat shock protein is shown in SEQ ID NO:
15. While feeding the above live bacteria, the immune cows are mixedly immunized with Helicobacter pylori natural antigen and recombinant antigen.
2. The preparation method according to claim 1, characterized in that: The preparation method of the recombinant antigen comprises: constructing recombinant plasmids of cytotoxin-associated protein A, vacuolating toxin, urease and heat shock protein respectively, and obtaining the recombinant antigen after prokaryotic expression and purification.
3. Immune milk obtained by the preparation method according to claim 1 or 2.
